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Abnormal uterine bleeding is the leading indication
for discontinuation of long-term progestin-only con-
traceptives (LTPOCs). Histological sections of endo-
metria from LTPOC-treated patients display abnor-
mally enlarged blood vessels at bleeding sites.
Paradoxically, a trend toward reduced endometrial
perfusion in LTPOC users has been reported in these
patients. We hypothesized that hypoxia/reperfusion-
induced free radical production inhibits the expres-
sion of angiopoietin-1 (Ang-1), a vessel stabilizing
factor, leaving unopposed the effects of endothelial
Ang-2, a vessel-branching and permeability factor.
Immunohistochemical studies confirmed selective
decreases in stromal cell Ang-1 in LTPOC-exposed
endometrium. To indirectly assess whether LTPOC
enhances endometrial free radical production, immu-
nostaining was conducted for the phosphorylated
form of the stress-activated kinases SAPK/JNK and
p38. These kinases were greatly increased in endome-
tria from LTPOC-treated patients. Interestingly, the
endothelial cells but not the stromal cells displayed
enhanced immunostaining for the phosphorylated
mitogen-activated kinase (pMAPK) after LTPOC treat-
ment. To further examine the effects of progestin,
hypoxia, and reactive oxygen species (ROS) on the
regulation of Ang-1 and Ang-2 as well as the activation
of MAPK, SAPK/JNK, and p38 by the relevant cell
types, we conducted in vitro studies with cultured
human endometrial stromal cells (HESCs) and human
endometrial endothelial cells (HEECs). Cultures of
HESCs were treated with vehicle control, estradiol
(E2), or with medroxyprogesterone acetate  E2 un-
der hypoxic and normoxic conditions. Although me-
droxyprogesterone acetate but not E2 increased Ang-1
expression, hypoxia greatly decreased Ang-1 protein
and mRNA expression. In contrast, HESCs did not ap-
pear to express Ang-2 protein or mRNA. Conversely,
cultured HEECs did not appear to express Ang-1, but
expressed Ang-2, the levels of which were significantly
increased by hypoxia. Hypoxia also induced the phos-
phorylation of SAPK/JNK and p38 in both cultured
HESCs and HEECs. Moreover, ROS such as that observed
after hypoxia/reperfusion resulted in the activation of
SAPK/JNK and p38 in HESCs and HEECs and inhibited
Ang-1 in cultured HESCs. These effects could be blocked
by oxygen radical scavengers. Consistent with the in
vivo studies, MAPK was activated after ROS treatment in
HEECs but not in HESCs. Our findings suggest that
LTPOC-induced endometrial bleeding occurs as a result
of hypoxia/reperfusion-induced free radicals that di-
rectly damage vessels and alter the balance of Ang-1 and
Ang-2 to produce the characteristic enlarged and per-
meable vessels that are prone to bleeding. (Am J
Pathol 2002, 161:979–986)
Long-term progestin-only contraceptives (LTPOC) provide
a highly practical solution to family-planning needs in de-
veloped and developing countries. Unfortunately, bleeding
in the early months of treatment often results in the discon-
tinuation of these otherwise safe and efficacious contracep-
tive methods. Several studies have shown that levonorg-
estrel (LNG) administered either locally to the uterine cavity
or systemically results in very significant morphological
changes in the endometrium including gland atrophy, ex-
tensive decidual transformation of the stroma, and in-
creased endometrial vasculature density.1–3 With long-term
LNG contraception, the vessels are enlarged, dilated, thin-
walled, and fragile, suggesting they are the product of
aberrant angiogenesis.4,5 Indeed, a number of investigators
have found a link between LTPOC-associated bleeding and
aberrant expression of the angiogenic agent vascular en-
dothelial growth factor (VEGF).6–8 Immunostaining for
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VEGF in endometrial glands and stroma was significantly
increased after LTPOC therapy, however, no correlation
was found between the VEGF-staining index and endome-
trial microvascular density.7
Although VEGF initiates angiogenesis, it is now known
that another family of proteins, the angiopoietins acting
via the Tie-2 receptor, are key regulators of the subse-
quent angiogenic steps including vessel branching, mat-
uration, and stabilization. Angiopoietin-1 (Ang-1) pro-
motes vascular integrity by optimizing the integration of
the endothelial cells with the surrounding supporting
cells. Recently it was reported that Ang-1 protects the adult
vasculature from bleeding by countering the permeability
effects observed after excess exposure to VEGF.9,10 In
contrast, Ang-2 is a partial antagonist of Ang-1/Tie-2 inter-
actions and is generally expressed in areas undergoing
vascular remodeling.11 Like VEGF, Ang-2 enhances vascu-
lar permeability and branching. Both hypoxia and VEGF
up-regulate Ang-2 expression in bovine microvascular en-
dothelial cells.12,13 Thus, Ang-1 and Ang-2 have comple-
mentary roles in vascular development and maintenance.
Therefore, it is plausible that altered regulation of Ang-1 and
Ang-2 is responsible for the pathological endometrial an-
giogenesis observed after LTPOC treatment.
In a recent pilot study, Hickey and colleagues14 dem-
onstrated a trend toward reduced endometrial perfusion
in long-term progestrogen users. We hypothesized that
this trend could reflect changes in the autoregulation of
endometrial blood flow that likely induce focal areas of
hypoxia. Recently, our laboratory has shown that Ang-2 is
expressed by endometrial endothelial cells and it is
strongly up-regulated by hypoxia and the inflammatory
agent phorbol myristate acetate.15 In addition, a number
of investigators have demonstrated that hypoxia also up-
regulates VEGF expression in endometrial stromal cells
and glands.16,17 Hypoxia is frequently followed by reper-
fusion and results in oxidative damage in the surrounding
tissues.18–20 Such oxidative stress has been shown to
induce SAPK/JNK and p38 kinases in a number of differ-
ent cell types.21–24 In addition, increased circulating lev-
els of lipid peroxides with concomitant depression of the
antioxidant vitamin E have been reported in users of
LTPOCs experiencing breakthrough bleeding.25 Thus,
we posit that LTPOC-induced hypoxia/reperfusion and/or
oxidative stress promotes the dysregulation of Ang-1 and
Ang-2 and gene activation resulting from the phosphor-
ylation of stress-activated kinases in endometrial stromal
and endothelial cells leading to fragile vessel formation
and ultimately breakthrough bleeding. The aim of this
study was to test this hypothesis by evaluating the effect
of progestins, hypoxia, and oxidative stress on the ex-
pression of the angiopoietins, MAPK, SAPK/JNK, and
p38 kinases in vivo and in vitro.
Materials and Methods
Tissues
Endometrial specimens for immunohistochemical studies
were obtained from women with normal menstrual cycles
before and 3 months after starting LTPOC with either
Norplant implants (n  6) or a LNG-releasing intrauterine
system (LNG-IUS; n  10). Pretreatment samples were
obtained from either the proliferative or secretory phases
of the cycle by blind pipelle biopsy (Unimar, Willon, CT).
In addition, endometrial specimens were obtained from
patients undergoing hysterectomies for myomas, and
transported on ice to a sterile laminar flow hood for en-
dometrial cell isolation and culture. Small portions were
formalin-fixed for dating by the histological criteria of
Noyes and colleagues.26 The use of endometrial tissue
for study was approved by the respective centers’ Insti-
tutional and Ethical Review Boards and written informed
consent was obtained before endometrial sampling.
Immunohistochemistry
Endometrial specimens from control and LTPOC-treated
patients were fixed in 4% paraformaldehyde and embed-
ded in paraffin. Peroxidase staining was conducted with
the ABC elite kit from Vector Laboratories (Burlingame,
CA) as described.15 Goat polyclonal antibodies to Ang-2
were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA). Rabbit polyclonal antibody to Ang-1 was ob-
tained from Alpha Diagnostic (San Antonio, TX). Rabbit
polyclonal antibodies to phosphorylated SAPK/JNK, p38,
and to total or phosphorylated MAPK were obtained from
Cell Signaling Technology (Beverly, MA).
Preparation of Primary Endometrial Cell Cultures
Human Endometrial Stromal Cells (HESCs)
HESCs were isolated and grown to confluence in a
37°C incubator using a basal medium as previously de-
scribed.27 For hormone treatment of HESCs, the experi-
mental period was initiated by the addition of vehicle
control or 108 mol/L estradiol (E2)  10
7 mol/L me-
droxyprogesterone acetate (MPA). The cells were treated
for 10 days, changing the medium every 3 to 4 days.
Cultures were then exposed to either normoxic or hypoxic
conditions for an additional 48 hours in a serum-free
defined medium as previously described.27 The latter
was achieved by placing select cultures in sealed cham-
bers containing a portable gas oxygen analyzer and a
beaker of water to maintain humidity. The chambers were
then purged with 5% CO2 and 95% N2 until the oxygen
analyzers read 0 to 1% O2 (12 to 14 mm Hg) and returned
to the incubator for 48 hours. No changes in O2 levels
were observed throughout the duration of the incuba-
tions. Experimental incubations were terminated by re-
moving the conditioned media and extracting the cell
lysate directly with either sodium dodecyl sulfate gel-
loading buffer for protein studies or with Tri-reagent (Sig-
ma, St. Louis, MO) for total RNA as previously de-
scribed.28
HEECs
HEECs were isolated and grown to confluence on
flasks coated with attachment factor (Cell Systems, Kirk-
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land, WA) in CS-C Complete Medium supplemented with
15% stripped fetal calf serum as described.29 The cells
were harvested by trypsin/ethylenediaminetetraacetic
acid (EDTA) and split 1:6 for four to six passages. The
experimental conditions were performed in a serum-free
defined medium as described.29 Select cultures were
treated with hypoxia and harvested for protein or total
RNA in the same manner as that described for the HESCs
(see above).
Reactive Oxygen Species (ROS) Generation
ROS were generated either by the addition of H2O2 (50
mol/L), FeCl2 (50 mol/L), or both for the indicated
times in defined media. Desferrioxamine (250 mol/L), or
dimethyl sulfoxide (DMSO) (28 mmol/L) were used to
block oxygen radical production. All reagents for ROS
were obtained from Sigma-Aldrich (St. Louis, MO).
Western Blotting
Western blotting was conducted on 5 to 15% gradient
gels (Bio-Rad, Hercules, CA) as previously described.28
Antibodies to phosphorylated SAPK/JNK, p38, and total
or phosphorylated MAPK were obtained from Cell Signal-
ing Technology. Antibodies to Ang-1 were from Alpha
Diagnostic and to Ang-2 from Santa Cruz Biotechnology.
Northern Blotting
Northern blots for Ang-1 and Ang-2 were conducted as
previously described.15
Reverse Transcriptase-Polymerase Chain
Reaction (RT-PCR)
RT-PCR for Ang-1 and Ang-2 was conducted as follows:
reverse transcription, first strand synthesis was per-
formed with Superscript First Strand Synthesis Systems
for RT-PCR (Life Technologies, Inc., Grand Island, NY)
using 1 to 5 g of total RNA and oligo(dT) (0.5 g/l) as
recommended by the manufacturer. The reaction was
terminated by incubating at 70°C for 15 minutes and
followed by treatment with RNase H for 20 minutes before
proceeding to the PCR step. PCR was then conducted
with Platinum PCR SuperMIX (Life Technologies, Inc.)
and 5 l of template DNA derived from the first strand
synthesis plus 200 mmol/L of sense and antisense prim-
ers for Ang-1 or Ang-2. The PCR primer pair for Ang-1
used is commercially available from R&D Systems
(Minneapolis, MN). The product yields a fragment 582 bp
long. The primer pair for Ang-2 was synthesized by Life
Technologies, Inc. using the sequence published by
Kim and colleagues.30 The product yields a fragment
1535 bp long. Thirty-five cycles were performed for the
PCR reaction.
RT-PCR for Tie-2 and GAPDH. Reverse transcription
was conducted in the same manner as that for Ang-1 and
Ang-2. The PCR step was conducted with the MPCR Kit
from Maxim Biotech Inc. (San Francisco, CA) that con-
tains primers for Tie-2 and GAPDH according to the
manufacturer’s instructions. The PCR product for Tie-2
results in a 212-bp fragment and the product for GAPDH
results in a 750-bp fragment.
Results
Immunohistochemical Studies
Ang-1 and Ang-2
Fixed endometrial specimens obtained before and af-
ter 3 months of LTPOC treatment were stained for Ang-1
and Ang-2. Figure 1 indicates that both secretory and
proliferative endometrium stained for Ang-1 in an even
manner. The highest degree of staining occurred in the
endothelium with low-level staining in the stroma and in
the glands. In contrast, high-dose local intrauterine proges-
tin (LNG-IUS)-exposed endometrium displayed patchy
Figure 1. Immunohistochemistry of Ang-1 in control and LTPOC-treated
human endometrium. Immunohistochemical staining for Ang-1 was per-
formed in human endometrium from proliferative phase (P), secretory phase
(S), and endometrium exposed to high-dose local intrauterine LNG (LTPOC)
for 3 months. Two different areas from the same pseudo-decidualized tissue
show the consistent blotchy staining pattern after LTPOC treatment reflected
by an area of low to no staining (bottom left) and an area of high staining
(bottom right). Studies were performed in paraffin-fixed sections as de-
scribed in Materials and Methods. Antigens are identified by brown peroxi-
dase staining. No staining was observed in the absence of primary antibody
(not shown).
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staining for Ang-1 with some areas of high staining and
some areas of low to no staining. The percentage of high
versus low staining is80% versus 20% (GK). In contrast to
that observed in cycling endometrium, most of the staining
for Ang-1 after LTPOC was observed in the stromal cells
(Figure 1). Unlike results observed with Ang-1, immuno-
staining for Ang-2 was mainly confined to endothelial cells
in both control and LTPOC-exposed endometria (Figure 2).
Because of the high levels of Ang-2 expressed in normal
cycling endometrium as well as that expressed after LT-
POC, it was difficult to ascertain whether LTPOC resulted in
a significant increase in endothelial cell Ang-2 expression in
the endometria of LNG-treated patients compared to con-
trols.
SAPK/JNK and p38
To assess whether stress pathways were activated
after LTPOC treatment, sections were stained for phos-
phorylated SAPK/JNK and p38. As can be seen in Figure
3, both p38 and SAPK/JNK were greatly activated after
LTPOC treatment in the stromal, endothelial, and glandu-
lar epithelial cells (n  5). MAPK was activated specifi-
cally in the endothelial cells after LTPOC. In contrast,
there was no difference in immunostaining for total MAPK
in LTPOC-treated versus controls (not shown).
Effects of Progestin, Hypoxia, and Oxidative
Stress on the Expression of Ang-1 and Ang-2 in
Cultured HESCs
As can be seen in Figure 4A, MPA greatly enhanced the
expression of Ang-1 mRNA by cultured HESCs com-
pared to those treated with vehicle control or E2. The
effects of progestin were similar in the presence or ab-
sence of E2. The expression of Ang-1 protein mimicked
the results observed for mRNA (Figure 4B, Western blot).
We next studied the effects of hypoxia after steroid
hormone treatment of cultured HESCs. As can be seen in
Figure 5, A and B, hypoxia abolished the MPA-induced
expression of Ang-1 mRNA and protein expression.
Because hypoxia is generally followed by reperfusion
leading to free radical generation, we investigated
whether oxidative stress may be involved in the genera-
tion of the fragile vessels and bleeding associated with
LTPOC treatment. To test this hypothesis, HESCs were
incubated under control or oxygen radical-generating
conditions as described in Materials and Methods. Figure
6A indicates that the production of ROS decreased the
Figure 2. Immunohistochemistry of Ang-2 in control and LTPOC-treated
human endometrium. Immunohistochemical staining for Ang-2 in human
endometrium from proliferative phase (P), secretory phase (S), and LTPOC-
exposed endometrium that in this case consisted of 3 months Norplant
treatment. Studies were performed in paraffin-fixed sections as described in
Materials and Methods. Antigens are identified by brown peroxidase staining.
No staining was observed in the absence of primary antibody (not shown).
Figure 3. Immunohistochemistry of SAPK/JNK, p38, and pMAPK in control
and LTPOC-treated human endometrium. Immunohistochemical staining for
SAPK/JNK, p38, and pMAPK was conducted in human endometrium from
control (proliferative phase) and endometrium exposed to high-dose intra-
uterine LNG (LTPOC) for 3 months. Studies were performed in paraffin-fixed
sections as described in Materials and Methods. Antigens are identified by
brown peroxidase staining. No staining was observed in the absence of
primary antibody (not shown).
Figure 4. Northern and Western blots for Ang-1 in hormone-treated HESCs.
HESCs were treated for 10 days with control (C), E2 (E), MPA (P), or E2 
MPA (EP) as described in Materials and Methods. A: Northern blot of
HESC-expressed Ang-1 mRNA, which was detected as described in Materials
and Methods. Loading efficiencies were assessed by ethidium bromide stain-
ing of the 28S and 18S ribosomal RNA. B: Western blot of HESC-expressed
Ang-1 protein was conducted as described in Materials and Methods.
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expression of Ang-1 mRNA. The addition of the antioxidant
desferrioxamine, a potent Fe-chelating agent, blocked the
reduction in Ang-1 mRNA consistent with the agent’s ability
to block ROS production31 and inhibit oxidative damage.
Similar results to those observed for mRNA were also ob-
served for Ang-1 protein by Western blotting (Figure 6B).
In contrast, there was no discernable level of Ang-2
mRNA as assessed by either Northern blotting or by
RT-PCR in either control or steroid-treated HESC cultures
with or without hypoxia or oxidative stress (Figure 7).
Effects of Hypoxia and Oxidative Stress on
HEEC Ang-1 and Ang-2 Expression
Although a recent study reported the presence of steroid
receptors in human endometrial endothelial cells
(HEECs),32 we and others have not been able to demon-
strate these findings.33,34 The lack of receptors was ob-
served in either early passaged33 or unpassaged endome-
trial endothelial cells (unpublished results). Hence, given
their apparent lack of steroid receptors, HEECs were not
treated with ovarian steroids. In contrast to the HESC cul-
tures, HEECs failed to express detectable levels of Ang-1
mRNA after conducting RT-PCR. Conversely, they ex-
pressed Ang-2 mRNA whereas HESCs did not (Figure 7).
No signal was observed when the reaction was performed
without the RT step. This is consistent with our previously
published results demonstrating that HEECs expressed
Ang-2 mRNA and these levels were greatly increased by
hypoxia.15
In addition, we demonstrate that as expected, HEECs
but not HESCs display a band for the Tie-2 receptor. As
a control, we show that GAPDH was expressed by all
cells (Figure 7).
Effects on the Activation of SAPK/JNK and p38
by Oxygen Radicals on Cultured Endometrial
Cells
Cultured HESCs were incubated under control or oxygen
radical-generating conditions. As can be seen in Figure
Figure 5. Northern and Western blots for Ang-1 in hormone-treated HESCs
under NX and HX. HESCs were treated for 10 days with control (C), E2 (E),
MPA (P), or E2  MPA (EP). At the end of this period, they were treated for
a further 48 hours under NX or HX in the presence of the appropriate
hormones as described in Materials and Methods. A: Northern blot of HESC-
expressed Ang-1. Loading efficiencies were assessed by ethidium bromide
staining of the 28S and 18S ribosomal RNA. B: Western blot of HESC-
expressed Ang-1 protein.
Figure 6. Northern and Western blots for Ang-1 in control and ROS-treated
HESCs. HESCs were treated under ROS-generating conditions for 24 hours as
described in Materials and Methods. A: Northern blot of HESC-expressed
Ang-1. Loading efficiencies were assessed by ethidium bromide staining of
the 28S and 18S ribosomal RNA. Lane 1, control; lane 2, FeCl2 (50 mol/L) 
H2O2 (50 mol/L); lane 3, FeCl2 (50 mol/L)  EDTA (50 mol/L)  H2O2
(50 mol/L); lane 4, FeCl2  H2O2  desferrioxamine (250 mol/L); and
lane 5, FeCl2 EDTA H2O2 desferrioxamine. Loading efficiencies were
assessed by ethidium bromide staining of the 28S and 18S ribosomal RNA. B:
Western blot of HESC-expressed Ang-1 protein. Lane 1, control; lane 2,
FeCl2 (50 mol/L)  H2O2 (50 mol/L); lane 3, FeCl2 (50 mol/L)  EDTA
(50 mol/L)  H2O2 (50 mol/L); lane 4, FeCl2  H2O2  desferrioxamine
(250 mol/L).
Figure 7. Ang-1, Ang-2, Tie-2, and GAPDH by RT-PCR from HEECs and
HESCs RNA. Total RNA was extracted from untreated HEECs or HESCs
treated with E2 (E), MPA (P), or E2  MPA (E  P) and semiquantitative
RT-PCR was conducted as described in Materials and Methods. The bottom
panel shows the corresponding HESC and HEEC RNA in which reverse
transcriptase was excluded from the reaction mixture. The primers used for
this negative control reflect those of GAPDH (GAP). Similarly, no product
was observed when reverse transcriptase was omitted and the reaction was
performed with primers for Ang-1, Ang-2, or Tie-2 (not shown).
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8, Western blot analysis showed that SAPK/JNK and p38
were greatly activated (ie, phosphorylated) under these
conditions whereas MAPK was not. The addition of the
oxygen radical scavenger DMSO greatly decreased the
activation of these kinases. Parallel blots were probed for
total MAPK (unphosphorylated) demonstrating equal lev-
els of protein in all samples.
Similarly, Western blot analysis of cultured HEECs in-
cubated under control or oxygen radical-generating con-
ditions demonstrated that both SAPK/JNK and p38 were
greatly activated by oxidative stress and DMSO de-
creased their activation (Figure 9). In contrast to the
effect on HESCs, oxidative stress resulted in the activa-
tion of MAPK in HEECs. The levels of total MAPK how-
ever, demonstrate similar loading levels.
Discussion
LTPOC treatment is often associated with vascular
changes that result in increased numbers of abnormally
enlarged fragile vessels and breakthrough bleeding.2,6
However, the exact mechanism(s) regulating this aber-
rant angiogenesis are not clearly understood. The finding
of a trend toward reduced perfusion in short-term pro-
gestrogen users suggests that LTPOC treatment results
in hypoxia.14 Tissue hypoxia is almost invariably followed
by reperfusion-induced free radical damage.18,35 It is
now known that oxidative damage is involved in the
pathogenesis of several human diseases. The classic
example of organ damage related to ischemia reperfu-
sion is represented by injury to the myocardium.35,36
Indeed, reperfusion not only causes a rapid degeneration
of endothelial cell function in the heart but also in the
lung, gut, and kidney and has been linked to systemic
sclerosis, Parkinson’s disease, and atherosclerosis.37,38
Thus, ischemia/reperfusion are two critical events that
may result from LTPOC treatment leading to the genera-
tion of oxidative stress, aberrant angiogenesis, and
breakthrough bleeding. Importantly, it is now known that
ROS play a major role in the activation of cell signaling
pathways leading to vascular pathologies.39,40
Indeed, SAPK/JNK activation has been shown in rat
cardiac myocytes after hypoxia/reperfusion.21,22 In cul-
tured hepatocytes, hypoxia alone was able to induce
JNK/SAPK activity, but not to the extent of that observed
when hypoxia was followed by reperfusion.23 Similarly,
p38, another stress-activated kinase, has been shown to
be activated in response to hypoxia in pulmonary micro-
vascular endothelial cells24 and by hypoxia/reperfusion
in cultured cardiac myocytes.22 Thus, the up-regulation
of these pathways may represent a tool to identify free
radical generation in affected tissues.
Our current findings demonstrated that proliferative
and secretory endometrium display immunohistochemi-
cal staining for Ang-1. Although staining was observed in
the vessels, RT-PCR conducted on total RNA isolated
from cultured HEECs did not produce the Ang-1 fragment
whereas the fragment was produced by HESCs. In con-
trast, HEECs expressed Ang-2 and Tie-2 mRNA (Figure
7). Thus, it is possible that the staining pattern reflects
binding of Ang-1 to its endothelial cell receptor, Tie-2. In
contrast to the pattern of Ang-1 expression in cycling
endometrium, an uneven pattern of immunostaining for
Ang-1 was observed in endometrial tissue exposed to
long-term LNG (local intrauterine or systemic delivery). It
is important to note, that because of the difficulty in
obtaining large numbers of tissues from LTPOC users,
the immunohistochemical studies in the present report
combined samples from patients treated with LNG deliv-
Figure 8. Western blots of SAPK/JNK and p38 after ROS treatment of HESCs.
The activation (ie, phosphorylation) of p38 and SAPK/JNK in HESCs was
detected after 30 minutes of ROS treatment as follows: lane 1, control; lane
2, H2O2 (50 mol/L); lane 3, FeCl2 (50 mol/L)  H2O2; lane 4, FeCl2
(50 mol/L)  EDTA (50 mol/L)  H2O2 (50 mol/L); lane 5, FeCl2 
H2O2  DMSO (28 mmol/L). Parallel blots were probed for total MAPK
(unphosphorylated) demonstrating equal levels of protein in all samples and
no effect by DMSO.
Figure 9. Western blots of SAPK/JNK, p38, and pMAP after ROS treatment of
HEECs. The activation of p38, SAPK/JNK, and pMAP in HEECs was detected
after 30 minutes of ROS treatment as follows: lane 1, control; lane 2, H2O2
(50 mol/L); lane 3, FeCl2 (50 mol/L)  H2O2; lane 4, FeCl2  H2O2 
DMSO (28 mmol/L). Blots were stripped and reprobed for total MAPK.
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ered either as Norplant implants or as a LNG-releasing
intrauterine system (LNG-IUS) and is limited to a total
number of 16 specimens.
Consistent with the hypothesis that localized areas of
hypoxia-reperfusion and the resultant formation of active
oxygen species impair Ang-1 production after LTPOC,
we show that both hypoxia and oxygen radical produc-
tion decrease expression of Ang-1 mRNA and protein in
cultured HESCs (Figures 5 and 6). Thus, we posit that
although progestin enhances cultured HESC Ang-1 ex-
pression in a normoxic, nonoxidative milieu, the inhibitory
effects of LTPOC observed in vivo result from decreased
endometrial perfusion, hypoxia/reperfusion, and para-
doxically decreased expression of Ang-1. Furthermore,
previous studies have shown hypoxia induced HEEC
Ang-2 expression.15 Increased Ang-2 promotes capillary
branching and increased permeability, and decreased
Ang-1 augments these effects and results in reduced
vessel stabilization via the Tie-2 receptor that is ex-
pressed by the endothelial cells (Figure 7). Thus, hypox-
ia/reperfusion and induction of free radicals could reduce
the local endometrial Ang-1:Ang-2 ratio leading to aber-
rant angiogenesis and the observed abnormal vessels
found in LTPOC-exposed endometria. This altered Ang-1:
Ang-2 ratio would occur within the context of a simulta-
neous induction in VEGF expression, exacerbating the
aberrant angiogenic stimulus and predisposition toward
leaky vessels.6,7
Further supporting our hypothesis that focal areas of
hypoxia-reperfusion lead to the formation of active oxy-
gen species after LTPOC treatment, is our finding of
preferential activation of SAPK/JNK and p38, in LTPOC-
exposed endometria (Figure 3). In addition, the genera-
tion of oxygen radicals in vitro greatly activated SAPK/
JNK and p38 in HESC and HEEC cultures (Figures 8 and
9). Interestingly, MAPK was activated only in the endo-
thelial but not the stromal cells after LTPOC treatment,
consistent with results observed in cultured HEECs (Fig-
ure 9).
Our present findings together with a previous study
demonstrating increased circulating levels of lipid perox-
ides, concomitant depression of the antioxidant vitamin
E, and a suggestion that vitamin E supplementation may
counteract these unwanted side-effects in LTPOC users
experiencing breakthrough bleeding25 have clinical im-
plications and suggest that antioxidant therapy may re-
duce the degree and extent of LTPOC-associated abnor-
mal uterine bleeding.
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